Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coulter IPO generates $30 mil.; B-1 therapy NDA slated for filing in mid/late 1998.

Executive Summary

COULTER B-1 THERAPY STUDIES IN RELAPSED LOW-GRADE 39424NON-HODGKIN'S LYMPHOMA patients are slated to begin this year, the Coulter Corp. spin-off said in a preliminary prospectus for its initial public offering. "To broaden the label indication, the company plans to carry out a randomized, controlled Phase III/IV clinical trial in patients with low-grade or transformed low-grade NHL in first or second relapse," the prospectus states. "The company currently plans to commence this clinical trial during the second half of 1997."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029630

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel